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Abstract
Background: The pathogenesis of HIV-associated dementia (HAD) is poorly understood. To date, detailed proteomic 
fingerprinting directly from autopsied brain tissues of HAD and HIV non-dementia patients has not been performed.
Result: Here, we have analyzed total proteins from the frontal cortex of 9 HAD and 5 HIV non-dementia patients. Using 
2-Dimensional differential in-gel electrophoresis (2-DIGE) to analyze the brain tissue proteome, 76 differentially 
expressed proteins (p < 0.05; fold change>1.25) were identified between HAD and HIV non-dementia patients, of 
which 36 protein spots (based on 3D appearance of spots on the images) were chosen for the mass spectrometry 
analysis. The large majority of identified proteins were represented in the energy metabolic (mitochondria) and signal 
transduction pathways. Furthermore, over 90% of the protein candidates are common to both HAD and other non-viral 
neurodegenerative disease, such as Alzheimer's disease. The data was further validated using specific antibodies to 4 
proteins (CA2, GS, CKMT and CRMP2) by western blot (WB) in the same samples used for 2D-DIGE, with additional 
confirmation by immunohistochemitsry (IHC) using frontal lobe tissue from different HAD and HIV+ non-dementia 
patients. The validation for all 4 antibodies by WB and IHC was in concordance with the DIGE results, lending further 
credence to the current findings.
Conclusion: These results suggest not only convergent pathogenetic pathways for the two diseases but also the 
possibility of increased Alzheimer's disease (AD) susceptibility in HAD patients whose life expectancy has been 
significantly increased by highly active antiretroviral therapy.
Background
HIV-1 associated dementia (HAD) is a common compli-
cation of HIV disease with a prevalence of at least 20% in
advanced HIV infection in the pre-highly active antiret-
roviral therapy (HAART) era [1]. Even in patients taking
HAART, milder forms of cognitive impairment remain
common and functionally significant [2]. The reasons for
the continued presence and development of HAD and its
milder forms, despite effective HAART are not clear. Fur-
thermore, due to the longevity of HIV patients after the
advent of HAART, the prevalence of HAD has increased
[3]. It has been hypothesized that Alzheimer's disease will
significantly increase among elderly HIV-infected indi-
viduals [4]. Thus, there is the possibility of HIV initiating
or facilitating a neurodegenerative process.
Various arrays and bioinformatic approaches have been
utilized to explore the pathogenesis of HAD [5-9]. Based
on the differentially expressed genes, many cellular pro-
cesses, including T-cell receptor-mediated signaling, sub-
cellular trafficking, transcriptional regulation, and a vari-
ety of cellular metabolic pathways have been identified.
However, there are two issues with these studies. First,
the transcriptomic gene expression has not been vali-
dated at the protein level. Second, several HAD patho-
genesis proteome-based studies are only confined to
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cultured cells and cerebrospinal fluid (CSF) [10-13]. To
date, protein changes directly in the native HIV-infected
brain tissue have not been reported.
Therefore, in the present study, we employed 2D-DIGE,
coupled with mass spectrometry, on the total protein
extracts from the autopsied human frontal cortex tissue
of HAD and HIV non-dementia patients to identify dif-
ferentially expressed protein candidates between these
two groups and to define the pathways and processes,
which might be involved in the pathogenesis of HAD,
along with any overlapping proteomic features between
HAD and other neurodegenerative diseases, such as AD.
Our study is unique in using the native brain tissues
obtained from HIV+ individuals at autopsy for a detailed
proteomic analysis.
Results and Discussion
Significant alteration of protein profiles in HAD brains as 
opposed to HIV non-demented brains
In this study, we determined the significantly altered pro-
teins between HAD and HIV non-dementia patients
using 2D-DIGE coupled with mass spectrometry. We
performed biological variance module analysis on 9 HAD
and 5 HIV non-dementia patients. A total of 958 protein
spots were detected on the master gel (893.14 ± 96.07
spots across all the individual gels), 76 of which were
found to change significantly in HAD brains compared to
HIV non-demented brains according to the criteria that a
spot had to be present in at least 16 of the 21 images; the
fold change had to be at least 1.25 with a P value less than
0.05. Figure 1 shows an image of the master gel. Among
these 76 altered proteins, 36 were chosen to be identified
by peptide mass fingerprinting, which was based on the
3-D appearance of spots on the images. Based on the data
obtained from the MASCOT database, 2 proteins were
found more than once and 3 gel spots contained more
than one protein, making the total number of unique pro-
teins to 31. Among them, 24 proteins increased signifi-
cantly while the remaining 7 proteins decreased
significantly. Table 1 shows the complete list of signifi-
cantly altered proteins in the HAD brains when com-
pared to HIV non-demented brains.
It is interesting to note that more than 90% of the pro-
teins identified in the current study have been reported
previously in relation to AD or other neurological dis-
eases (Table 1), thereby lending further credence to our
observations. Among them, 9 of 31 proteins have already
been reported to interact with HIV directly or indirectly.
According to their molecular functions, these 9 proteins
can be categorized into 4 groups: proteins involved in
metabolic pathways/processes; proteins involved in signal
transduction pathways/processes; and antigen presenting
protein. In the following section, we will discuss these
nine proteins by their functions and three other function-
ally similar proteins, which have neither been reported
previously in HIV infection nor in the context of other
neurological diseases.
a. Proteins involved in metabolic pathways/processes
In the current study, we have found both creatine kinase
(CK; EC 2.7.3.2) and glutamine synthetase (GS; EC
6.3.1.2) significantly increased in HAD brains in compari-
son to HIV non-demented brains. They are involved in
energy related metabolism (arginine and proline metabo-
lism and nitrogen metabolism, respectively). Further-
more, they are two of the three major specifically
oxidized proteins in AD brains [14]. CK plays an impor-
tant role in facilitating energy transfer within cells with
high energy flux or requirements by catalyzing the
reversible transfer of a phosphoryl group between ade-
nosine-5'-triphosphate (ATP) and creatine. Cytoplasmic
brain CK (BB form) and ubiquitous mitochondrial CK
(uMtCK), among the four isoforms of CK, have been
reported co-expressed [15] at various levels throughout
the entire brain and serve as an efficient energy buffering
and shuttle system in the brain [16]. For uMtCK, the
change in AD brains is not significant although a sharp
decrease of its activity has been reported [17]. Our results
on the HAD brain proteome suggest that HIV can manip-
ulate the energy production or transfer for its own use by
altering uMtCK expression since HIV-1 Tat peptide can
fuse with human brain CK, and this fusion can increase
CK activity after being transduced into PC12 cells [18].
GS is a ubiquitous enzyme, which plays an important role
in recycling the glutamate. It is mainly localized in astro-
glial cells. It has been used as a biomarker of oxidative
stress [19] and potential diagnostic marker of AD [20]. Its
presence is enhanced in neurological diseases associated
with reactive astrogliosis [21]. Previous in vitro studies
have also reported a positive correlation of GS with HIV
replication [22] or the concentration of HIV glycoprotein
120 [23]. Our findings provide in vivo evidence that HIV
infection can alter GS expression in human brain, thereby
impairing the glutamine/glutamate cycle.
Further, in this context, it is important to mention that
we identified another protein, elongation factor Tu, mito-
chondrial (EF-Tu), which plays a vital role in energy-
related cellular metabolic processes and can interact with
HIV. It is involved in the mitochondrial protein transla-
tion and its mutations are associated with combined oxi-
dative phosphorylation deficiency, which can lead to fatal
encephalopathy [24]. Previous studies have shown that
EF1a, one of its family members, can interact with the
entire HIV-1 Gag polyprotein [25]. Therefore, the
increase of EF-Tu in HAD brains, observed in the current
study, raises the possibility that HIV-host interaction
might partly contribute to the abnormal oxidative phos-
phorylation. Thus, HIV might be able to trigger oxidative
stress in the HAD brains, which is a vital step in theZhou et al. Molecular Neurodegeneration 2010, 5:27
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development of neurodegeneration. Our findings also
concur with a previous in vitro study that HIV-1 infection
d o e s  i n d u c e  t h e  g e n e r a t i o n  o f  r e a c t i v e  o x y g e n  s p e c i e s
(ROS) [26]. Further in vivo studies on enzyme activity and
protein modifications are needed in the context of neuro-
logical manifestations of HIV disease.
b. Proteins involved in signal transduction pathways/
processes
Two important proteins, stathmin (STMN1) and growth
factor receptor-bound protein2 (GRB2), identified in our
study, are involved in mitogen activated protein kinase
(MAPK) signalling pathways, which are known to play
multiple roles in HIV disease and NK effector functions
[27,28]. Up-regulation of STMN1 in HAD brains was
found in our study, whereas a decrease of STMN1 had
b e e n  p r e v i o u s l y  r e p o r t e d  i n  A D  a n d  D S  b r a i n s  [ 2 9 ] .
STMN1 belongs to a class of regulatory proteins related
to microtubule dynamics [30] and is vital for cellular pro-
cesses, including intracellular transport, maintenance of
cell shape and cell polarity [31]. It is widely distributed in
the neuronal cell body, dendrites, axons, and growth
cones [32] and is involved in the destabilization of micro-
tubule, which is essential for axon and dendrite differenti-
ation, growth, and maintenance and even the generation
of neuronal size, shape, and compartmentalization [33].
In addition, Nishi et al. [34] have demonstrated that
STMN1 expression can inhibit enhancement of HIV-1
particle production by suppressing cytokine signaling-1.
Our results indicate that alteration of STMN1 might be
one of the positive host responses upon HIV infection at
Figure 1 Master gel from from 2D-DIGE experiment. Master gel was chosen by DeCyder software automatically based on the spot numbers iden-
tified across all the gels. On this gel, one HAD sample (Cy5-labeled), one HIV non-dementia patient (Cy3-labeled) and an internal standard (Cy2-la-
beled) were included. First dimension, IEF pH 3 to 10 NL (right to left); second dimension, SDS (8-18%) polyacrylamide gel electrophoresis. White circles 
and numbers indicate identified proteins that are listed in Table 1.Zhou et al. Molecular Neurodegeneration 2010, 5:27
http://www.molecularneurodegeneration.com/content/5/1/27
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Table 1: Identified proteins and related pathways and neurological diseases summary
KEGG pathway spot no Ac. No. Name ratio P value Related Neurological disease
Glycolysis/
Gluconeogenesis
pathway
387 P09972 Fructose-bisphosphate aldolase C 
[Homo sapiens]
1.69 0.0009 Schizophrenia, bipolar disorder, 
and depression [100]
471 P00338 L-lactate dehydrogenase A chain [Homo 
sapiens]
1.5 0.039
439 P07195 L-lactate dehydrogenase B chain (LDH) 
[Homo sapiens]
1.43 0.028
412 P14550 Alcohol dehydrogenase [NADP+] [Homo 
sapiens]
1.36 0.028
605 P60174 Triosephosphate isomerase [Homo 
sapiens]
-1.32 0.02 Neurodegeneration [101]
581 Q53G35 Phosphoglycerate mutase 1 (Brain) 
variant (Fragment) [Homo sapiens]
-1.6 0.043 AD [102]
Oxidative 
phosphorylation 
pathway
518 B3KP20 cDNA FLJ30970 fis, clone 
HEART2000444, highly similar to Homo 
sapiens phospholysine 
phosphohistidine inorganic 
pyrophosphate phosphatase (LHPP), 
mRNA [Homo sapiens]
1.57 0.043 AD [85]
522 P36543 V-type proton ATPase subunit E 1 [Homo 
sapiens]
1.55 0.0068
658 O75947-2 (ATP5H)Isoform 2 of O75947. [Homo 
sapiens]
1.48 0.015
587 P47985 Cytochrome b-c1 complex subunit 
Rieske, mitochondrial [Homo sapiens]
1.38 0.013
634 O96000 NADH dehydrogenase (ubiquinone) 1 
beta subcomplex subunit 10 [Homo 
sapiens]
-1.42 0.0059
Nitrogen metabolism 
pathway
363 P15104 Glutamine synthetase [Homo sapiens] 1.85 0.0007 AD [20]
578 P00918 Carbonic anhydrase 2 [Homo sapiens] -3.11 0.009 Mental retardation,
AD [103,104]
Arachidonic acid 
metabolism pathway
494 P16152 Carbonyl r Carbonyl reductase [NADPH] 
1 [Homo sapiens]
2 0.014 AD [105]
Purine metabolism 
pathway
787 P22392 Nucleoside diphosphate kinase B [Homo 
sapiens]
-1.33 0.0061 DS, AD [106]
Arginine and proline 
metabolism pathway
369 P12532 Creatine kinase, ubiquitous 
mitochondrial [Homo sapiens]
1.47 0.0006 Alzheimer's and Pick's Disease [17]
Glutathione 
metabolism pathway
624 P09211 Glutathione S-transferase P [Homo 
sapiens]
-1.64 0.024 Parkinson's disease, AD [107,108]
MAPK signalling 
pathway
738 P16949 Stathmin [Homo sapiens] 1.48 0.031 DSand AD [29,109]
608 P62993 Growth factor receptor-bound protein 2 
[Homo sapiens]
1.29 0.04 AD [110]Zhou et al. Molecular Neurodegeneration 2010, 5:27
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Calcium signalling 
pathway
496 B4DKM5 cDNA FLJ60120, highly similar to 
Voltage-dependent anion-selective 
channel protein 2 [Homo sapiens]*
1.57 0.021
411 P50148 Guanine nucleotide-binding Protein G(o) 
subunit alpha [Homo sapiens]
1.36 0.026 Familial Alzheimer's disease [49]
Axon guidance 
pathway
230 Q16555 Dihydropyrimidinase-related protein 2 
[Homo sapiens]
1.57 0.025 AD [14]
Parkinson's disease 
pathway
384 Q7KYV2 H5 [Homo sapiens]* 1.37 0.035 Autosomal-recessive juvenile 
parkinsonism [111]
Antigen processing 
and presentation 
pathway
189 P11142 Heat shock cognate 71 kDa protein 
[Homo sapiens]
1.39 0.022 AD [59]
N/A 393 O00154 (ACOT7)Isoform 6 of O00154. [Homo 
sapiens]
1.64 0.0018
394 Q2TU84 Aspartate aminotransferase [Homo 
sapiens]
1.51 0.0048
350 P49411 Elongation factor Tu, mitochondrial 
[Homo sapiens]
1.35 0.008 Infantile Encephalopathy [24]
723 P61601 Neurocalcin-delta [Homo sapiens]* 1.57 0.043 AD [53]
475 B4DGP9 cDNA FLJ54102, highly similar to Beta-
soluble NSF attachment protein [Homo 
sapiens]
1.53 0.033
458 P62879 Guanine nucleotide-binding protein G(I)/
G(S)/G(T) subunit beta-2 [Homo sapiens]
1.73 0.0089 AD [46]
784 A8MVL5 Putative uncharacterized protein PRDX5 
[Homo sapiens]
-1.88 0.032 AD and parkinson [112,113]
Note: Most proteins in this table are involved in gene-ontology metabolic process except those proteins marked by *.
Table 1: Identified proteins and related pathways and neurological diseases summary (Continued)
the protein level, which can inhibit the virion assembly
and production.
GRB2 is an adaptor protein involved in signal transduc-
tion/cell communication and T-cell activation [35]. GRB2
coupled to Son-of-sevenless-1 (SOS-1), which can acti-
vate the RAS/MAPK pathway [36], and form one of the
primary components of signal transduction cascade [37].
In neurodegenerative processes it directly interacts with
amyloid precursor protein (APP) and presenilin (PS1),
which play an important role in the onset of AD [38].
Moreover, increased levels of Grb3-3, an isoform of Grb2,
were seen in PBMCs from HIV-1 infected subjects [39].
In the current study, a mild increase of Grb-2 protein was
seen in HAD brains, which complements previous stud-
ies on AD brains. Its increase in HAD brains is probably
triggered by HIV-1 since Grb3-3 can be induced by HIV
Tat and Nef proteins independently [40]. In the context of
HAD, it might be involved in the MAPK activation and
possibly tau hyper-phosphoylation, which needs to be
elucidated in future.
The guanine nucleotide-binding proteins (G proteins)
families also play a crucial role in signal transduction.
They function as molecular switches between extracellu-
lar events and intracellular effectors. Through the cou-
pling between their receptors and several heterotrimeric
G - p r o t e i n s  i n  N K  c e l l s ,  t h e  C ,  C C ,  C X C  a n d  C X 3 C
chemokines can activate NK cells and induce intracellular
signalling pathways in the NK cells [41,42]. In the present
study, we found a significant up-regulation in both Go
subunit alpha and beta-2. Our results are consistent with
previous  in vitro array studies [7]. It might indicate a
stronger host antiviral response by activating the NK cellsZhou et al. Molecular Neurodegeneration 2010, 5:27
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and then death of the infected host cells. In this context, it
is important to reiterate that the CC chemokine
RANTES, MIP-1b and the CXC chemokine SDF-1a,
which signal through M-tropic HIV-1 co-receptors CCR5
and CCR3 and T-tropic HIV-1 co-receptor CXCR4
respectively, are activated by G proteins [43,44]. In non-
viral neuro-degeneration, G-protein can also couple with
two of the three causative gene products of familial
Alzheimer's disease, APP [45] and PS1 [46]. Data
(reviewed by Cowburn [47]) have suggested that the neu-
rochemical pathology of AD includes severe disruption of
the neurotransmitter receptor/G-protein mediated phos-
phatidylinositol hydrolysis and adenylyl cyclase signal
transduction pathways. β2 subunit and β γ complex of G-
proteins have been reported to participate in chemokine-
induced NK cell chemotaxis [48] and mediate apoptosis
[49], respectively. In the context of HIV, further studies
are needed to explore the mechanism of how HIV inter-
feres with G proteins expression and utilizes G proteins
to manipulate the signalling pathways for its survival.
Another important protein interacting with HIV identi-
fied in this study is neurocalcin, which is a Ca2+-binding
protein distributed abundantly in the central nervous sys-
tem and has been reported to play a role in neuronal sig-
nalling [50]. So far, at least 6 isoforms of neurocalcin have
been identified. Neurocalcin δ is expressed mainly in glial
cells [51]. It has been reported that one of the target pro-
teins of neurocalcin δ is S100β [51], which has been
shown to be up-regulated in HIV infection and very
important to HAD neuropathogenesis [52]. To the
author's knowledge, neurocalcin δ has been only reported
to be site down-regulated in the temporal lobe of AD
brains [53,54] without comparison to control brain. In
our study, we found an up-regulation of neurocalcin in
the frontal cortex of HAD brains and our results suggest
that neurocalcin δ and S100β complex might participate
in the pathogenesis of HAD by inducing gliosis, growth of
dystrophic neurites, and calcium-mediated neuronal cell
loss.
c. Antigen presenting and other proteins
Heat shock cognate 71 kDa protein (HSC-71) was mildly
but significantly increased in the HAD brains. HSC-71 is
the constitutively expressed member of the heat shock
protein 70 (Hsp70) family and has 85% homology with
Hsp70. Hsp70 protein level can increase due to HIV
infection or oxidative stress [55,56]. Furthermore, Hsp70
can trigger an increased immune response by incorporat-
ing into the membrane of HIV virions and prevent HIV
induced astrocytes apoptosis [57]. In the context of neu-
rodegeneration, HSC71 plays more important roles. For
instance, it can interact with the cytoplasmic domain of
APP in the presence of proteasome inhibitors. This indicates
that HSC-71 might participate in proteasome structural
maintenance and mis-folded protein conformational rec-
ognition [58]. Although HSC-71 has been reported to
have an insignificant down-regulation in the AD brains
[59], it appears more oxidatively modified and possibly
glycosylated in the AD brains [14,60]. Taking these obser-
vations in the context of our study, the increase in the
expression of HSC-71 could be a consequence of HIV
infection or increased oxidative stress seen during HIV
infection [61].
Worthy of noting is that we have found three function-
ally similar proteins (ACOT7, FLJ54102 and FLJ60120),
which have neither been reported previously in HIV
infection nor in the context of other neurological dis-
eases. ACOT7 or Acyl-CoA thioesterases (EC 3.1.2.2.) are
enzymes that catalyze the hydrolysis of CoA esters of var-
ious molecules to the free acid plus coenzyme A (CoA)
[62], which differentiates them from long-chain acyl-CoA
synthetases because long-chain acyl-CoA synthetases
ligate fatty acids to CoA, to produce the CoA ester [63].
They are implicated in the regulation of intracellular lev-
els of CoA esters, the corresponding free acid, CoASH
and cellular processes involving these compounds.
ACOT8 under recently revised nomenclature was identi-
fied as hACTEIII [64] and hTE [65], which can interact
with and activate the HIV-1 Nef protein. So far, only long
chain acyl-CoA synthetases have been reported to be
related to neurodegenerative disease [66]. Interestingly,
we found up-regulation of the ACOT7 protein uniquely
in the HAD brains implying its likely interaction with
HIV.
The second protein is cDNA FLJ54102, a highly similar
protein to beta-soluble N-ethylmaleimide-sensitive factor
(NSF) attachment protein. We observed an up-regulation
of FLJ54102 in the HAD brains. Soluble NSF attachment
proteins (SNAPs) are highly conserved proteins, which
are involved in intracellular membrane fusion and vesicu-
lar trafficking. There are three individual isoforms of
SNAPs: α, β, and γ [67]. Among them, β-SNAP is brain
specific and it has been reported that maximal levels of
its expression are in the hippocampus [68]. Schiavo [69]
showed that β-SNAP, NSF, SNAP receptor, and the cal-
cium-binding protein synaptotagmin (SYT) assemble
cooperatively to form a docking and fusion complex. HIV
Tat has been reported to be able to fuse with NSF and
inhibit the extrocytosis [70], while SNAP receptor has
been reported to be involved in fusion events of endo-
somal Gag-RNA complexes with the plasma membrane
to generate virions through an endosome-dependent
route [71]. The expression of SNAPs has also been shown
to be significantly reduced in the AD and DS brains [72].
The third is cDNA FLJ60120, highly similar to voltage-
dependent anion-selective channel protein (VDAC) 2.
VDAC is a mitochondrial outer-membrane protein,
which plays an important role in the pore formation and
cytochrome c release [73]. It can regulate cell death byZhou et al. Molecular Neurodegeneration 2010, 5:27
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Page 7 of 20
binding to B-cell CLL/lymphoma 2 (Bcl-2) family pro- or
anti- apoptotic protein [74,75]. It can also regulate the
mitochondrial function by controlling metabolite fluxes
through the mitochondrial membrane [76,77]. It can
impact on glucose metabolism by directly binding to gly-
colytic enzymes [74]. More importantly, it has been
reported to be involved in neurodegenerative disorders
and mental retardation [78-81]. By binding VDAC, HIV
Vpr can induce apoptosis through a direct effect on the
mitochondrial permeability transition pore complex
(PTPC) [82]. Three of human VDACs have been cloned
and termed, VDAC1, VDAC2 and VDAC3. VDAC2 has
been shown to over-express in the AD brains [74]. Our
findings on HAD brains suggest possible association with
apoptosis and the synaptic loss in HAD brains due to the
impairment of energy pathways during HIV infection.
Apart from these proteins discussed at above, other
identified proteins in the current study so far haven't been
reported to be related to HIV infections. However, some
proteins, especially carbonic anhydrase 2 (CA2) and car-
bonyl reductase [NADPH] 1, changed dramatically in the
HAD brains (Table 1). Moreover, both of them have been
reported to change in AD brains and are involved in AD
pathogenesis. Thus, our results might indicate that HIV is
able to alter those candidate proteins that directly or indi-
rectly affect neurological functions. This sheds light on
some novel candidate host proteins that possibly interact
with HIV and modulate neuropathogenesis.
Pathway and network analysis
For annotation and pathway analysis of these identified
proteins, Metacore and DAVID were used. The 31 identi-
fied differentially expressed proteins were transferred
into the official gene symbol ID code based on their cor-
responding Swiss-prot database accession numbers.
There were 19 statistically significant locations
(FDR<0.05, p < 0.01), the details of which are shown in
the Additional file 1. Among them, the mitochondrion,
cytoplasm, cytoplasmic part, cytosol and mitochondrial
inner membrane rank the top 5 according to the statisti-
cal significance. Functionally, most of them are enzymes,
while several transporting proteins and generic binding
protein were also observed (see Additional file 2).
The pathway analysis showed that the Glycolysis/Glu-
coneogenesis and Oxidative phosphorylation KEGG
pathways were highly enriched (enrichment score are
3.82 and 1.21, respectively) and statistically significant (p
= 3.7e-6 and 1.6e-2, respectively). The key enzymes of
Glycolysis pathway, TPI and PGAM1, were significantly
down-regulated while other identified proteins within the
Glycolysis pathway (ALDOC, AKR1A1, LDHA and
LDHB) were up-regulated (Figure 2). In the Oxidative
phosphorylation pathway, the proteins involved in com-
plex III and complex IV (LHPP, ATP6V1E1, ATP5 H,
UQCRFS1) were up-regulated, only NDUFB10, an
important protein in complex I, was down-regulated (Fig-
ure 3). The association between enriched genes and
related processes within these two pathways is shown in
Figure 4 and Figure 5.
We next examined the gene-ontology biological process
networks. There are 48 processes that are highly signifi-
cant based on our data with FDR<0.005 and p < 0.0005
(FDR cut off value, stringently<0.05, normally<0.25), (see
Additional file 3 for a complete list). The most significant
one is the generation of precursor metabolites and energy
process (p = 2.095e-9), which contains 11 identified pro-
teins out of 31. The most involved is the metabolic pro-
cess (p = 1.604e-5), which contains more than 90% of the
identified proteins (Figure 6). The identified proteins are
involved in diverse metabolic processes, including carbo-
hydrate metabolism, energy metabolism, lipid metabo-
lism, nucleotide metabolism and amino acid metabolism.
I t  i s  b r o a d l y  a c c e p t e d  t h a t  m e t a b o l i c  p a t h w a y s / p r o -
cesses are closely related to neurodegenerative diseases. It
has been shown that the impairment of energy metabo-
lism can exacerbate synaptic dysfunction, neuronal
injury, which together may lead to neurodegenerative dis-
orders [83]. The oxidative phosphorylation system
(OXPHOS), using glucose as critical substrates, normally
provides more than 95% of ATP used for cellular energy.
Inefficient glycolysis plays a crucial role in the pathogene-
sis of AD [84]. Further, the mitochondrial genes in com-
p l e x  I  o f  O X P H O S  h a v e  b e e n  d e m o n s t r a t e d  t o  b e
significantly down-regulated in AD and Parkinson's
brains [85,86]. In the context of HIV, it has also been
shown that HIV-1 targets the energy generating system of
the host cells by affecting mitochondrial DNA and pro-
tein [87]. HIV envelope glycoprotein gp120 can impair
glucose metabolism in vitro and in vivo [88,89]. Further-
more, HIV-1 matrix protein, p17, can stimulate gluco-
neogenesis by inducing the expression of Fructose 1, 6
bisphosphatase, which can convert fructose-1, 6-bisphos-
phate to fructose 6-phosphate and produce NADPH [90].
Also, it has been reported that HIV can reduce the activ-
ity of complex I by down-regulating the expression of
NDUFA6 at protein level [91].
Supporting these arguments, our pathway/process
analysis has shown that most of the identified proteins in
the current study were involved in metabolic pathways or
processes. Figure 2 and Figure 3 shows the Glycolysis and
Oxidative phosphorylation KEGG pathways. We have
observed a significant decrease in the levels of two key
enzymes of Glycolysis pathway (TPI and PGAM1) and
complex I of Oxidative phosphorylation pathway
(NDUFB10), while complex III and complex IV were up-
regulated. These findings overlap with AD brains as well
[85]. It is probably due to a great demand on energy pro-
duction. In addition, it has been shown that HIV-1 infec-Zhou et al. Molecular Neurodegeneration 2010, 5:27
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tion does induce ROS, thereby leading to T cell death
[26]. Our results provide a further explanation that HIV
might influence the production of ROS through regulat-
ing the Oxidative phosphorylation pathway. Figure 6
shows the metabolic network, which includes identified
proteins in the current study (marked with a circle), and
the proteins within the metabolic network and closely
interact with the identified proteins. All edges are sup-
ported by at least 1 reference from the literature. Collec-
tively, this complex alteration of proteins provides strong
support for abnormalities in metabolic pathways/pro-
cesses during HAD in humans.
The overlap between HAD and non-viral dementia
It is interesting that more than 90% of the proteins identi-
fied in the current study share an overlap with proteins
reported from other neurodegenerative brains (Table 1).
Although the alteration of these pathways/processes and
proteins are possibly more generalized in neurodegenera-
tive disorders rather than specifically abnormal in indi-
vidual diseases, the critical overlap between HAD and
non-viral neurodegenerative disorders, such as AD, is
worthy of attention. Previous studies have shown that
brain infections, such as herpes simplex, are related to the
occurrence and development of AD process [92-94]. In
addition, Brosseau et al. [95], have shown the first case of
HIV-associated dementia with characteristics of
Alzheimer's disease in a patient with AIDS, which sup-
ports the functional and neurophysiological relevance of
the data shown in this study . Our findings a t the pro-
teomic level further raise the possibility that HIV might
initiate or facilitate a neurodegenerative process. Our
findings are consistent with previous reports at the
genetic level [96]. However, until detailed proteomic fin-
gerprinting is available from various virus-mediated neu-
rodegenerative diseases (such as HSV encephalitis), it is
difficult to rule out whether these overlaps at the protein
level exist only between HAD and non-viral neurodegen-
erative diseases or human brain responds to different
pathogens similarly. Nonetheless, our study is the first to
provide this tantalizing evidence in favor of this major
proteomic overlap between HAD and non-viral neurode-
generation, which in the future may clarify the involve-
ment of any pathogenic etiology in non-viral
neurodegenerative processes.
Functional validation
Western blotting was performed to validate the 2D-DIGE
data using the same samples for a subset of 4 proteins:
carbonic anhydrase 2 (CA2), glutamine synthetase (GS),
creatine kinase, ubiquitous mitochondrial (CKMT), and
dihydropyrimidinase-related protein 2 (CRMP2). CA2 is
down-regulated protein in the current proteomic study
and its deficiency is closely related to other neurological
disease, therefore it was chosen for validation by western
blot. CA2 was recognized by Carbonic Anhydrase II anti-
body at size of 29 kDa (Figure 7A). It was expressed in
both HAD and HIV non-dementia brains, but its relative
abundance was slightly higher in HIV non-dementia
patients as opposed to the dementia group (FC = 1.2, p <
0.05, Figure 7E). This is consistent with our IHC result.
This is probably due to the high abundance of this pro-
tein, which can influence the fold-change accuracy.
Moreover, this difference was more prominent when
severe dementia and non-dementia patients were com-
pared (FC = 6.7).
In contrast, the GS, CKMT, and CRMP2 were up-regu-
lated proteins, which changed from mild (FC<1.5) to
moderate (1.5<FC<2). Apart from their direct relevance
in neurological disease, they were also chosen for valida-
tion because of their increase in fold-change in 2D-DIGE
data. They were recognized by their specific antibodies at
sizes 42, 47 and 63 kDa, respectively (Figures 7B, C and
7D). The western blot results of these three proteins fol-
lowed the trend of 2D-DIGE data (p < 0.05) but not in
numeracy (Figure 7E), with the exception of two samples
where they were not recognized by the antibodies (sam-
ple #2434 and #H0011db with GS and CKMT). This is
possible because the low sensitivity of western blot tech-
niques/antibodies compared to 2D-DIGE/CyDye.
Although some noticeable sample-to-sample variation
within the same group was observed, no statistical rela-
tionship with dementia stage was found apart from some
visual differences in relationship. Figure 7 shows the 3D
DeCyder interpretation of all 4 proteins together with
their corresponding western blot results.
Further, we also performed additional validation using
immuno-histochemistry to confirm the results obtained
from 2D-DIGE experiments and also western blots using
the frontal lobe brain tissue sections derived from
patients with and without HAD for the same 4 proteins
used in WB analysis. The staining of three up-regulated
proteins (GS, CKMT and CRMP2) was in concordance
with the 2D-DIGE results. All three proteins stained for
astrocytes, especially in the superficial cortex proximal to
the leptomeninges. Protein GS stained on astrocytes in
the white matter, whereas it was much weaker when com-
pared to staining in the cortex. Considerably significant
difference was observed between GS staining in HAD
and HIV non-dementia brains. For CKMT, apart from
astrocytes, it occasionally stained on scattered microglia.
More prominent and positive staining for CKMT and
CRMP2 was found in the HAD brain as opposed to HIV
non-dementia brain. Possibly owing to the low-abun-
dance of CKMT and CRMP2, these differences are not so
prominent, but these results are fully consistent with the
mild change of these two proteins in 2D-DIGE results.
CA2 protein was found predominantly in relatively smallZhou et al. Molecular Neurodegeneration 2010, 5:27
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Figure 2 Illustration of altered components of HAD frontal cortex in the Glycolysis/Gluconeogenesis pathway. Figure 2 depict the classical 
Glycolysis/Gluconeogenesis pathway obtained from the KEGG pathway database http://www.genome.jp/kegg/. The genes, whose corresponding 
proteins have been found to differentially change in the current study, are highlighted in red and are denoted by dots. The protein details are listed 
in Table 1.Zhou et al. Molecular Neurodegeneration 2010, 5:27
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sized neurons, while the bigger size neurons were nega-
tive for CA2 staining. The biological reason for which is
not clear. In addition, it was weakly stained on some
astrocytes as well. Compared to HIV non-dementia
brain, the staining of CA2 in the HAD brain was very
focal in some areas, while almost absent in others. In con-
trast, in HIV non-dementia brain, the staining was well
spread implying that the CA2 expression could be pathol-
ogy-specific, which need to be elucidated in future study.
Overall, the CA2 staining was comparatively lesser in the
HAD brain as opposed to non-HAD brain, which further
confirmed the trend of 2D-DIGE, but not in numeracy.
The reason for this could be the high abundance of this
protein  in vivo, which cannot accurately provide high-
fold change comparison. Alternatively, the section from
HAD patient is rich in CA2-related pathology confirmed
by western blot results, which also showed the variation
within group. Thus, a bigger sample size is needed to elu-
cidate this hypothesis in future studies. Figure 8 shows
immunohistochemical staining results for all 4 antibodies
discussed in this section.
Conclusion
Our study is the first demonstration of evidence showing
overlapping proteins between viral (HIV) and non-viral
neurodegenerative diseases. Although the majority of
proteins identified in this study have been previously
reported in relation to other neurodegenerative or psy-
chiatric diseases, these findings do provide a strong foun-
dation not only for understanding possible mechanisms
of HAD, but also provide a much needed foundation for
clarifying the possible involvement of a pathogenic etiol-
Figure 3 Illustration of altered components of HAD frontal cortex in the Oxidative phosphorylation pathway. Figure 3 depict the classical Ox-
idative phosphorylation pathway obtained from the KEGG pathway database. The genes, whose corresponding proteins have been found changed 
in the current study, are highlighted in red and are denoted by dots. The protein details are listed in Table 1.Zhou et al. Molecular Neurodegeneration 2010, 5:27
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Page 11 of 20
ogy in non-viral neurodegenerative diseases. Further-
more, we also observed a significant involvement of
Glycolysis and Oxidative phosphorylation, the two
important energy related metabolic pathways, in the
HAD brains, which has been fully demonstrated in the
current study at the pathway level. Interestingly, the
involvement of these pathways in HAD also coincides
with their involvement in other neurodegenerative dis-
eases, such as AD and PD.
Materials and methods
Patient details and brain tissue collection
Brain tissue samples were obtained from HIV-1-infected
patients with or without HAD through the National
Neuro-AIDS Tissue Consortium (NNTC, Request
#R203) and the Westmead Hospital, Sydney, Australia
(Reference No: 5465). Samples were collected at post-
mortem, shipped frozen on dry ice and stored frozen at -
70°C until use. Frontal cortex of male patients 9 with
HAD and 5 without were used for this study due to its
importance to motor impairment and involvement in AD
[97,98]. The average age for HAD and non-HAD patients
was 43.57 ± 14.77 and 50.2 ± 11.88, respectively, (P =
0.41). Clinical profiles of all patients are shown in Addi-
tional file 4. This study was conducted according to the
principles expressed in the Declaration of Helsinki. Use
of samples in this study was approved by Institutional
Review Board and the Ethics Committee of the NNTC
Figure 4 Heatmap showing evidence of protein enrichment in the Glycolysis/Gluconeogenesis pathway. Figure 4 shows the heatmap depict-
ing enrichment of proteins in the Glycolysis/Gluconeogenesis pathway. Rows signify enriched genes and the columns signify related processes within 
the pathway. Green cells indicate that the corresponding genes and terms are associated positively according to the literature, whereas the black cells 
indicate the association not yet been reported.Zhou et al. Molecular Neurodegeneration 2010, 5:27
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Allocations, the University of Sydney and the Westmead
Hospital individually. The family members of the patients
have given written, informed consent for the use of
autopsied brain tissue. For the diagnostic criteria for
HAD, the criteria defined by the American Academy of
Neurology 1991 were used (American Academy of Neu-
rology. Nomenclature and research case definitions for
neurological manifestations of HIV type 1 infection 1:
Report of a working group of AAN of neurology and
AIDS task force, 1991).
Sample preparation
In each case, 30 mg of frozen brain tissue was measured
on dry ice and then transferred into a 2 mL Eppendorf
tube. The tissues were lysed in 1 mL of 4°C lysis buffer (7
M urea, 2 M thiourea, 30 mM Tris, 4% CHAPS, 2% ASB,
1% Sigma protease inhibitor cocktail), vortexed for 30
seconds and cooled for 1 minute on ice (repeat 25 cycles),
sonicated for 1 minute at 4°C and cooled for 1 minute on
ice (repeat 3 cycles), and centrifuged for 50 minutes at
14000 rpm at 4°C. Protein concentrations were deter-
mined using the 2-D Quant kit (GE Healthcare), as per
manufacturer's instructions.
Protein labeling with CyDyes
Protein samples were labelled with CyDyes (GE Health-
care), as per manufacturer's instructions. 25 μg of total
protein from each sample was mixed in an Eppendorf
tube (Eppendorf, Düsseldorf, Germany) and labelled with
Cy2 minimal dye, and 50 μg protein was taken from the
Figure 5 Heatmap showing evidence of protein enrichment in the Oxidative phosphorylation pathway. Figure 5 is the heatmap showing en-
richment of proteins in the Oxidative phosphorylation pathway. Rows signify enriched genes and the columns signify related processes within the 
pathway. Green cells indicate that the corresponding genes and terms are associated positively according to the literature, whereas the black cells 
indicate the association not previously reported.Zhou et al. Molecular Neurodegeneration 2010, 5:27
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Figure 6 GeneGo network. Proteins identified in this study were uploaded to the Metacore software (GeneGo corp). The generated network shows 
significant involvement of proteins in the metabolic process. Interactions between proteins are denoted by lines. Green lines indicate activation, while 
the red lines indicate inhibition. Nodes are represented by distinct shapes and colors.Zhou et al. Molecular Neurodegeneration 2010, 5:27
http://www.molecularneurodegeneration.com/content/5/1/27
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Figure 7 3D DeCyder image and corresponding Western blot analysis for four representative proteins. Each pair of protein spots (Cy3-and 
Cy5-labeled) in 3D views is shown together with the corresponding western blot analysis (A: CA2, B: GS, C: CKMT, D: CRMP2). The 3D peak of each 
protein was generated based on the pixel intensity versus pixel area, whereby the peak area correlated with the distribution of a given protein spot 
on the gel and then normalized by the standard (Cy-2-labeled). 3D images were obtained from DeCyder software. The western blot results correlated 
with the 2D-DIGE data. Sample orders in western blot analysis were the same as shown in Additional file 4, from right to left. Sample #2434 and 
#H0011db were absent in GS and CKMT proteins. Semi-quantitative western blot analysis (E) represented the relative protein level (standardized by 
Actin) in HAD and HIV non-dementia patients. Fold-change in values was labelled on the top of each paired comparison. The quantification analysis 
demonstrated the trend similar to the one observed in 2D-DIGE for HAD patients when compared to HIV non-dementia patients (p < 0.05).Zhou et al. Molecular Neurodegeneration 2010, 5:27
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mix and used as an internal standard on each gel for the
subsequent 2D electrophoresis and image analysis. In
parallel, 50 μg proteins of each sample were labelled with
either Cy3 or Cy5, and the dyes scrambled within each
group to avoid possible dye bias. The sample volumes
were adjusted to 18 μL with labelling buffer (7 M urea, 2
M thiourea, 4% CHAPS, 30 mM Tris), followed by addi-
tion of 1 μL dye (working solution) to each individual
sample. The samples were left on ice for 30 minutes in the
dark, followed by adding 1 μL of 10 mmol/L lysine to stop
the reaction.
2D Electrophoresis and image analysis
One sample from each of the CyDye groups was mixed
together and adjusted to final concentrations of 1% DTT,
1% IPG buffer at a total volume of 350 μL with lysis buffer
(7 M urea, 2 M thiourea, 4% CHAPS, 0.04% bromophenol
blue) and was used to rehydrate 17 cm IPG strips (pH 3-
10, non-linear; Bio-Rad) overnight. First dimension iso-
electric focusing (IEF) was carried out with IPGphor II
(GE Healthcare). The strips were focused at a constant
temperature of 20°C with approximately 55 kVh (150 V
for 3 hours, gradient to 300 V for 1 minute, 300 V for 5
Figure 8 Immunohistochemical staining of four representative proteins in HAD and HIV non-dementia patients in the frontal lobe. Immu-
nohistochemical evaluation of CA2 (a, b, c and d), GS (e, f, g and h), CKMT (i and j) and CRMP2 monoclonal antibodies (k and l) for staining the frontal 
lobe from HAD and HIV non-dementia patients. Relatively less CA2 staining, but more focal and neuronal staining was observed in HAD patient, as 
seen at different magnifications (a: x20, b: x40) compared to a more spread out astrocyte staining in HIV non-dementia patients (c: x20 and d: x40). 
The red arrows on b and d showed neuronal staining, while the blue arrows show astrocytic staining. Extensive GS staining was seen in HAD brain (g: 
x20 and h: x40), whereas in the HIV non-dementia patient the staining was significantly weaker (e: x20 and f: x40). The staining with CKMT and CRMP2 
antibodies showed relative weaker signals due to low antigen levels. However, the clear differences are still noticeable for both antibodies. For CKMT, 
in HAD patient (j), there are strongly stained cells, along with several weakly stained cells around, whereas in HIV non-dementia patients (i), only very 
limited number of stained cells with only fewer weakly stained cells around. This contrast was stronger in CRMP2 staining (k and l) in comparison to 
CKMT.Zhou et al. Molecular Neurodegeneration 2010, 5:27
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hours, gradient to 8000 V for 4 hours, 8000 V for 4 hours,
gradient to 400 V for 30 minutes, 400 V for 4 hours). The
strips then were incubated with equilibration buffer (50
mM Tris-HCL pH 8.8, 6 M urea, 30% glycerol, 2% sodium
dodecyl sulfate, 0.02% bromophenol blue) containing 65
mM DTT for 15 minutes, followed by 130 mM iodoacet-
amide in equilibration buffer for the next 15 minutes. The
second dimension SDS-PAGE was performed by mount-
ing the IPG strips onto 8% to 18% polyacrylamide gradi-
ent gel (Jule Precast Gels, USA) and running the gels in
the Protean II multi cell electrophoresis system (Bio-Rad)
at 16 mA/gel for the initial hour and 25 mA/gel at 10°C
constantly until bromophenol blue reached the bottom of
the gel. Following this, the gels were scanned on a
Typhoon Trio variable mode imager (GE Healthcare) at
100 microns resolution to produce a Cy2, Cy3 and Cy5
image for each gel according to the manufacturer's proto-
col. The images were cropped with ImageQuant software
(GE Healthcare) and analyzed by automated Difference
In-gel Analysis (DIA) and Biological Variation Analysis
(BVA) using Decyder software version 6.5 (GE Health-
care). After the gels were scanned, they were removed
from the glass plates fixed with 10% methanol, 7% acetic
acid overnight, stained with Coomassie Brilliant Blue
G250 (Coomassie Brilliant Blue G250 0.5 g, Ammonium
sulphate 50 g, 85% Phosphoric Acid 6 mL in 500 mL
water and add 125 mL methanol before use) overnight
and de-stained with 1% acetic acid overnight.
Mass Spectrometry and Protein identification
Spots selected for protein identification were manually
excised using a scalpel, de-stained in 60% (v/v) 50 mM
ammonium bicarbonate (pH 7.8), 40% (v/v) acetonitrile
and then dehydrated in 100% acetonitrile for 1 minute
before being dried in a vacuum centrifuge. Gel pieces
were rehydrated in 10 μL trypsin solution (12 ng/μl por-
cine modified sequencing grade trypsin in 50 mM ammo-
nium bicarbonate, pH 7.8) at 4°C for 1 hour. Excess
trypsin solution was removed and 15 μL of 50 mM
ammonium bicarbonate (pH 7.8) was added prior to
incubating overnight at 37°C. For MALDI-TOF MS anal-
ysis, 1 μL of peptide was spotted onto a target plate with
an equal volume of matrix solution (10 mg/mL α-cyano-
4-hydroxycinnamic acid in 70% (v/v) acetonitrile, 1% (v/
v) TFA). Mass spectra were acquired in the mass:charge
range of 875-3500 m/z on a QSTAR XL mass spectrome-
ter equipped with an oMALDI source (Applied Biosys-
tems Inc., Foster City, CA, USA). The monoisotopic peak
masses were subjected to database searching against the
MSDB comprehensive non-redundant database using
MASCOT vr 2.0 (Matrix Science, London, UK). Parame-
ters for protein identification included searching with a
mass error tolerance of 50 ppm per peptide, 1 missed
tryptic cleavage, and allowing oxidation of methionine as
an optional modification. Confident matches were
defined by the MASCOT score and statistical signifi-
cance (p < 0.05), the number of matching peptides and
the percentage of total amino acid sequence covered by
those matching peptides. Peptide mixtures that provided
poor initial mass spectra were concentrated and desalted
using C18 PerfectPure reverse-phase micro-columns
(Eppendorf, Düsseldorf, Germany) according to the man-
ufacturer's instructions and eluted in matrix solution
directly onto the target plate. MALDI-TOF MS was then
performed as described above.
Functional analysis of protein findings
Once identified with mass spectrometry, the gene encod-
ing counterpart of each individual protein was searched
in the Swiss-prot database http://www.expasy.org based
on their Swiss-prot database accession numbers. After-
wards, the gene symbol and the fold change of each pro-
tein were loaded to Metacore http://portal.genego.com
and DAVID http://david.abcc.ncifcrf.gov/ to determine
the pathways and biological processes associated with
each individual protein. The analysis was performed
using the algorithm within the software. The pathways
and processes statistically significant to the data set were
represented by maps in the database and network,
respectively.
Functional Validation of proteins using Western blotting 
and Immuno-histochemistry
Western blot and immunohistochemistry were employed
to validate the 2D-Dige data. A subset of the same sam-
ples for the 2D-Dige study was used for the western blot.
40 ug of proteins were separated by 12% SDS-PAGE and
then transferred to PVDF membranes (Millipore, USA)
or nitrocellulose membranes (Amersham, USA) using
Bio-Rad apparatus (Bio-Rad, USA). Membranes were
blocked in 5% skim milk powder or 5% BSA in Tris-buff-
ered saline (TBS) (20 mM Tris and 0.9% NaCl, pH 7.4) for
1 hour at room temperature. Following that, they were
incubated for 2 hours at room temperature with each of
the following primary antibodies: rabbit anti-Carbonic
Anhydrase II (1:10000), Creatine kinase MT (1:75), Glu-
tamine Synthetase (1:2000) (Abcam, US) and with
another primary antibody rabbit anti-CRMP2 (1:4000)
(Abcam, US) incubated overnight at 4°C. Mouse anti-
Actin (1:6000, DAKO, USA) was used as control anti-
body. Membranes were washed four times with TTBS
(TBS with 0.05% Tween20) and then incubated for 1 hour
with anti-rabbit HRP-conjugated secondary antibody
(Dako, USA; 1:6000) followed by chemiluminescence
ECL detection (GE, USA) and exposure to autoradiogra-
phy film (Kodak, France). Films were scanned with HP
scanjet8200 (HP, USA) and the images were collected and
analysed using Imagel software http://rsbweb.nih.gov/ij/.Zhou et al. Molecular Neurodegeneration 2010, 5:27
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Statistically significant differences between patients were
estimated with the Mann-Whitney test (P-value < 0.05).
Different samples were used for immuno-histochemis-
try. The serial sections of frontal lobes from 1 HAD ver-
sus 1 HIV non-dementia patients were used for the
experiment. Patient details were well documented previ-
ously (Patient A and D in [99]). Tissues were fixed in 20%
formalin, followed by paraffin embedding. Sections were
cut into 6 μm thick for immuno-histochemical staining.
Heat antigen retrieval was performed using citrate buffer
(pH 6.0) or EDTA buffer (pH 8.0). 3% H2O2, NH4Cl, Gly-
cine, goat serum and Bovine Serum Albumin (BSA)
(Aurion) blocking steps were used. Slides then were incu-
bated over night at 4°C or at room temperature with the
same primary antibodies used for western blot: rabbit
anti-Carbonic Anhydrase II (1:800), Creatine kinase MT
(1:10), Glutamine Synthetase (1:100) and rabbit anti-
CRMP2 (1:100) (Abcam, US), washed in PBS and then
incubated for one hour with the swine anti-rabit HRP-
conjugated secondary antibody (1:100; Dako, USA). The
detection were made using DAB kit (Dako, USA). The
images were captured using a Leica microscope and anal-
ysed neuropathologically.
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